These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18318942)

  • 1. HIV infection, visceral leishmaniasis and Guillain-Barré syndrome in the same patient: a case report.
    Kumar N; Pandey K; Das VN; Sinha PK; Topno RK; Lal CS; Bimal S; Verma N; Das P
    Ann Trop Med Parasitol; 2008 Mar; 102(2):185-8. PubMed ID: 18318942
    [No Abstract]   [Full Text] [Related]  

  • 2. Miltefosine for Indian visceral leishmaniasis.
    Agarwal PK
    N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12606744
    [No Abstract]   [Full Text] [Related]  

  • 3. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India.
    Thakur CP; Sinha PK; Singh RK; Hassan SM; Narain S
    Trans R Soc Trop Med Hyg; 2000; 94(6):696-7. PubMed ID: 11198660
    [No Abstract]   [Full Text] [Related]  

  • 4. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
    Sundar S; Singh A
    Expert Rev Anti Infect Ther; 2013 Feb; 11(2):117-9. PubMed ID: 23409817
    [No Abstract]   [Full Text] [Related]  

  • 5. Functional recovery of untreated human immunodeficiency virus-associated Guillain-Barré syndrome: a case report.
    Schreiber AL; Norbury JW; De Sousa EA
    Ann Phys Rehabil Med; 2011 Nov; 54(8):519-24. PubMed ID: 22036304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction.
    Kumar N; Pandey K; Das VN; Sinha PK; Topno RK; Verma N; Lal CS; Das P; Bhattacharya SK
    Ann Trop Med Parasitol; 2007 Oct; 101(7):649-51. PubMed ID: 17877883
    [No Abstract]   [Full Text] [Related]  

  • 7. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
    Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
    Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
    Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
    Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of splenic marginal zone lymphoma in a HIV-negative patient with visceral leishmaniasis.
    Vase MØ; Hellberg YK; Larsen CS; Petersen E; Schaumburg H; Bendix K; Ravel C; Bastien P; Christensen M; d'Amore F
    Acta Haematol; 2012; 128(1):20-2. PubMed ID: 22572474
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
    Patole S; Burza S; Varghese GM
    Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the management of visceral leishmaniasis.
    Sundar S; Kumar A
    Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miltefosine for visceral leishmaniasis.
    Eibl H
    N Engl J Med; 2000 Mar; 342(12):894-5. PubMed ID: 10733376
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapy for visceral leishmaniasis.
    Wkly Epidemiol Rec; 2002 Jun; 77(25):210-2. PubMed ID: 12132132
    [No Abstract]   [Full Text] [Related]  

  • 17. Miltefosine for Indian visceral leishmaniasis.
    Roca B
    N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12608397
    [No Abstract]   [Full Text] [Related]  

  • 18. Breakthrough in the management of visceral leishmaniasis.
    Thakur BB
    J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
    [No Abstract]   [Full Text] [Related]  

  • 19. Miltefosine for visceral leishmaniasis.
    Sherwood JA
    N Engl J Med; 2000 Mar; 342(12):895. PubMed ID: 10733377
    [No Abstract]   [Full Text] [Related]  

  • 20. An oral drug for leishmaniasis.
    Jacobs S
    N Engl J Med; 2002 Nov; 347(22):1737-8. PubMed ID: 12456848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.